Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Shares Issued
Ratios

RAPT Therapeutics (RAPT) EBIAT: 2020-2023

Historic EBIAT for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to -$30.9 million.

  • Therapeutics' EBIAT fell 34.54% to -$30.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$116.8 million, marking a year-over-year decrease of 39.32%. This contributed to the annual value of -$116.8 million for FY2023, which is 39.32% down from last year.
  • As of Q4 2023, Therapeutics' EBIAT stood at -$30.9 million, which was up 1.57% from -$31.4 million recorded in Q3 2023.
  • Therapeutics' 5-year EBIAT high stood at -$12.4 million for Q2 2020, and its period low was -$31.4 million during Q3 2023.
  • For the 3-year period, Therapeutics' EBIAT averaged around -$22.5 million, with its median value being -$20.9 million (2022).
  • Data for Therapeutics' EBIAT shows a maximum YoY crashed of 47.73% (in 2023) over the last 5 years.
  • Over the past 4 years, Therapeutics' EBIAT (Quarterly) stood at -$12.7 million in 2020, then tumbled by 40.79% to -$17.9 million in 2021, then declined by 28.01% to -$23.0 million in 2022, then plummeted by 34.54% to -$30.9 million in 2023.
  • Its EBIAT was -$30.9 million in Q4 2023, compared to -$31.4 million in Q3 2023 and -$25.3 million in Q2 2023.